Exelixis
EXEL
#1725
Rank
โ‚ฌ9.17 B
Marketcap
32,12ย โ‚ฌ
Share price
-1.16%
Change (1 day)
50.55%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): 0,26ย โ‚ฌ

According to Exelixis's latest financial reports the company's current EPS (TTM) is 0,27ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of 0,55ย โ‚ฌ a decrease over its 2021 EPS that were of 0,71ย โ‚ฌ.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)0,26ย โ‚ฌ-52.85%
20220,55ย โ‚ฌ-22.97%
20210,71ย โ‚ฌ100%
20200,36ย โ‚ฌ-65.09%
20191,02ย โ‚ฌ-53.91%
20182,22ย โ‚ฌ333.96%
20170,51ย โ‚ฌ-260.61%
2016-0,32ย โ‚ฌ-58.75%
2015-0,77ย โ‚ฌ-42.45%
2014-1,34ย โ‚ฌ5.3%
2013-1,27ย โ‚ฌ43.48%
2012-0,89ย โ‚ฌ-264.29%
20110,54ย โ‚ฌ-165.88%
2010-0,82ย โ‚ฌ-32.54%
2009-1,22ย โ‚ฌ-17.65%
2008-1,48ย โ‚ฌ75.86%
2007-0,84ย โ‚ฌ-25.64%
2006-1,13ย โ‚ฌ8.33%
2005-1,04ย โ‚ฌ-42.86%
2004-1,82ย โ‚ฌ30.34%
2003-1,40ย โ‚ฌ-5.23%
2002-1,48ย โ‚ฌ-0.65%
2001-1,49ย โ‚ฌ-51.88%
2000-3,09ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
3,38ย โ‚ฌ 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
3,07ย โ‚ฌ 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
1,76ย โ‚ฌ 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
3,83ย โ‚ฌ 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
13,65ย โ‚ฌ 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
13,59ย โ‚ฌ 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
1,79ย โ‚ฌ 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-9,65ย โ‚ฌ-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,81ย โ‚ฌ-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA